In Vivo CRISPR Base Editing: Verve-102 Offers 'One-and-Done' Permanent Cholesterol Reduction
Verve Therapeutics' in vivo CRISPR base editing program, VERVE-102, utilizes lipid nanoparticles to permanently disable ...
Read More →Verve Therapeutics' in vivo CRISPR base editing program, VERVE-102, utilizes lipid nanoparticles to permanently disable ...
Read More →Landmark trials like SELECT and FLOW have proven that GLP-1 agonists offer profound cardiovascular and renal protection,...
Read More →mRNA-4157/V940, a personalized neoantigen therapy developed by Moderna and Merck, has demonstrated a 44% reduction in re...
Read More →The p-tau217 blood biomarker test has revolutionized Alzheimer’s diagnosis, offering over 90% accuracy and replacing c...
Read More →AI healthcare breakthroughs in 2026 include Örebro University's 97% accurate dementia detection via EEG, AI-designed mo...
Read More →Global regulators are cracking down on AI-generated harmful content, with the EU banning "nudifier" apps, Australia enfo...
Read More →In response to AI-driven cyber threats, the US has signed an Executive Order streamlining model reviews and centralizing...
Read More →The Technology Innovation Institute's Falcon-H1R 7B shatters the "bigger is better" AI paradigm, outperforming models se...
Read More →The Great American Artificial Intelligence Act of 2026 introduces comprehensive federal AI regulation, mandating third-p...
Read More →Boston Dynamics' Atlas humanoid robot has begun operational field tests at a Hyundai manufacturing facility, marking a m...
Read More →VivaTech 2026 and the WEF’s 2026 Technology Pioneers cohort highlight a critical shift in AI: the move from consumer m...
Read More →Pope Leo has issued a landmark papal declaration on AI ethics, demanding that artificial intelligence development be str...
Read More →